AMN Stock Analysis: AMN Healthcare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.291m USD | 12M Return: 77.9% | US0017441017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.8M
EPS Trend: -81.0%
Qual. Beats: 2
Rev. Trend: -54.3%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AMN Healthcare Services, Inc. is a U.S.-based provider of technology-enabled healthcare workforce solutions and staffing services, serving acute and sub-acute care hospitals, skilled nursing facilities, rehabilitation clinics, schools, pharmacies, and other healthcare facilities. Founded in 1985 and headquartered in Dallas, Texas, the company operates through three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions.
Its service portfolio spans travel nurse staffing, allied health staffing, crisis and labor disruption staffing, international nurse permanent placement, locum tenens, physician and advanced practice staffing, healthcare interim leadership, executive search, revenue cycle solutions, and language services. AMN also delivers vendor management systems (VMS), workforce optimization tools, and outsourced solutions, including its teletherapy platform, Televate, for K-12 schools. The healthcare staffing sector in which AMN operates is shaped by persistent clinical labor shortages, an aging patient population, and growing reliance on contingent labor to flex hospital capacity, which has made outsourced workforce management and VMS platforms a significant component of the broader health care services industry. AMN markets its offerings under brands such as AMN Healthcare, Nursefinders, OGrady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith.
- Travel nurse demand and bill rates normalize from pandemic highs
- Nurse staffing volumes drive consolidated quarterly revenue
- Vendor management systems scale within Workforce Solutions segment
| Net Income: 104.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 7.03 > 1.0 |
| NWC/Revenue: 2.88% < 20% (prev -0.08%; Δ 2.96% < -1%) |
| CFO/TA 0.20 > 3% & CFO 470.8m > Net Income 104.9m |
| Net Debt (446.8m) to EBITDA (343.9m): 1.30 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.7m) vs 12m ago 3.43% < -2% |
| Gross Margin: 27.79% > 18% (prev 29.84%; Δ -2.05% > 0.5%) |
| Asset Turnover: 150.1% > 50% (prev 125.2%; Δ 24.88% > 0%) |
| Interest Coverage Ratio: 5.61 > 6 (EBIT TTM 199.8m / Interest Expense TTM 35.6m) |
| A: 0.04 (Total Current Assets 869.3m - Total Current Liabilities 770.5m) / Total Assets 2.36b |
| B: 0.55 (Retained Earnings 1.29b / Total Assets 2.36b) |
| C: 0.09 (EBIT TTM 199.8m / Avg Total Assets 2.29b) |
| D: 0.46 (Book Value of Equity 741.3m / Total Liabilities 1.62b) |
| Altman-Z'' = 3.12 = A |
| DSRI: 0.67 (Receivables 382.5m/457.5m, Revenue 3.43b/2.77b) |
| GMI: 1.07 (GM 29.84% / 27.79%) |
| AQI: 0.89 (AQ_t 0.58 / AQ_t-1 0.66) |
| SGI: 1.24 (Revenue 3.43b / 2.77b) |
| TATA: -0.15 (NI 104.9m - CFO 470.8m) / TA 2.36b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of September 20, 2026, the stock is trading at USD 34.26 with a total of 1,073,000 shares traded. Over the past week, the price has changed by +2.76%, over one month by -0.81%, over three months by +10.59% and over the past year by +77.88%.
Current recommended Stop Loss: 30.70 (which is 10.4% or 2.5 ATR below the current price).
AMN Healthcare has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold AMN.
- StrongBuy: 1
- Buy: 2
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 35.6 | 3.8% |
P/E Trailing = 12.3941
P/E Forward = 26.178
P/S = 0.376
P/B = 1.7268
P/EG = 1.7113
Revenue TTM = 3.43b USD
EBIT TTM = 199.8m USD
EBITDA TTM = 343.9m USD
Long Term Debt = 742.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.79m USD (from shortTermDebt, last quarter)
Debt = 808.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.9m
Net Debt = 446.8m USD (calculated: Debt 808.7m - CCE 361.8m)
Enterprise Value = 1.74b USD (1.29b + Debt 808.7m - CCE 361.8m)
Interest Coverage Ratio = 5.61 (Ebit TTM 199.8m / Interest Expense TTM 35.6m)
EV/FCF = 3.96x (Enterprise Value 1.74b / FCF TTM 439.1m)
FCF Yield = 25.26% (FCF TTM 439.1m / Enterprise Value 1.74b)
FCF Margin = 12.79% (FCF TTM 439.1m / Revenue TTM 3.43b)
Net Margin = 3.05% (Net Income TTM 104.9m / Revenue TTM 3.43b)
Gross Margin = 27.79% ((Revenue TTM 3.43b - Cost of Revenue TTM 2.48b) / Revenue TTM)
Gross Margin QoQ = 30.58% (prev 26.76%)
Tobins Q-Ratio = 0.74 (Enterprise Value 1.74b / Total Assets 2.36b)
Interest Expense / Debt = 4.41% (Interest Expense 35.6m / Debt 808.7m)
Taxrate = 36.10% (59.3m / 164.2m)
NOPAT = 127.7m (EBIT 199.8m * (1 - 36.10%))
Current Ratio = 1.13 (Total Current Assets 869.3m / Total Current Liabilities 770.5m)
Debt / Equity = 1.09 (Debt 808.7m / totalStockholderEquity, last quarter 741.3m)
Debt / EBITDA = 1.30 (Net Debt 446.8m / EBITDA 343.9m)
Debt / FCF = 1.02 (Net Debt 446.8m / FCF TTM 439.1m)
Total Stockholder Equity = 685.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.59% (Net Income 104.9m / Total Assets 2.36b)
RoE = 15.31% (Net Income TTM 104.9m / Total Stockholder Equity 685.1m)
RoCE = 13.99% (EBIT 199.8m / Capital Employed (Equity 685.1m + L.T.Debt 742.9m))
RoIC = 8.94% (NOPAT 127.7m / Invested Capital 1.43b)
WACC = 6.99% (E(1.29b)/V(2.10b) * Re(9.61%) + D(808.7m)/V(2.10b) * Rd(4.41%) * (1-Tc(0.36)))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.65 | Cagr: 1.77%
[DCF] Terminal Value 77.97% ; FCFF base≈365.7m ; Y1≈419.2m ; Y5≈616.9m
[DCF] Fair Price = 228.2 (EV 9.28b - Net Debt 446.8m = Equity 8.84b / Shares 38.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -81.02 | EPS CAGR: -41.23% | SUE: 3.48 | # QB: 2
Revenue Correlation: -54.30 | Revenue CAGR: -7.78% | SUE: 0.96 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.23 | Chg30d=+34.08% | Revisions=+58% | Analysts=9
EPS current Year (2026-12-31): EPS=3.29 | Chg30d=+23.53% | Revisions=+75% | GrowthEPS=+141.7% | GrowthRev=+22.8%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=-13.76% | Revisions=-25% | GrowthEPS=-71.5% | GrowthRev=-20.5%
[Analyst] Revisions Ratio: +43% (up=20, down=7)